
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Immunol., 31 January 2024
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1372991
This article is a correction to:
Identification and Validation of Immune-Related Methylation Clusters for Predicting Immune Activity and Prognosis in Breast Cancer
A Corrigendum on:
Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer
By Yang A, Zhou Y, Kong Y, Wei X, Ye F, Zhang L, Zhong X, Li M, Lu S, An X and Xiao W (2021) Front. Immunol. 12:704557. doi: 10.3389/fimmu.2021.704557
In the published article, there was an error regarding the affiliations for Weikai Xiao. The affiliation of Weikai Xiao should only be 7, but not 1.
In the published article, there was also an error in the Funding statement. This previously stated: The approval number of the National Natural Science Foundation of China was displayed as “8203066”. And the approval number of Guangzhou basic and applied basic research project (approved in 2021).
The correct Funding statement appears below.
FUNDING
This research is funded by the National Natural Science Foundation of China (approval No.: 82003066), Guangzhou basic and applied basic research project (202102020168), and special science and Technology Fund (Doctoral entrepreneurship project) of Guangdong People’s Hospital and Guangdong Provincial Medical Research Fund (a2021080).
The authors apologize for these error and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: DNA methylation, IRMGs, immune infiltration, prognosis, breast cancer
Citation: Yang A, Zhou Y, Kong Y, Wei X, Ye F, Zhang L, Zhong X, Li M, Lu S, An X and Xiao W (2024) Corrigendum: Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer. Front. Immunol. 15:1372991. doi: 10.3389/fimmu.2024.1372991
Received: 19 January 2024; Accepted: 22 January 2024;
Published: 31 January 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Yang, Zhou, Kong, Wei, Ye, Zhang, Zhong, Li, Lu, An and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xin An, YW54aW5Ac3lzdWNjLm9yZy5jbg==; Weikai Xiao, eGlhb3drQHN5c3VjYy5vcmcuY24=
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.